Research has identified and described a pro-inflammatory cytokine network shared by four rheumatic conditions that may be particularly active in patients with severe disease.
‘Nothing but NET[osis]’: RheumMadness 2022 Anti-NET Antibodies Scouting Report
Neutrophil extracellular traps (NETs) contribute to the pathogenesis of multiple autoimmune diseases. And research has shown that patients with antiphospholipid syndrome (APS) have higher levels of circulating anti-NET antibodies than healthy controls, indicating a potential biomarker.
Broadcasting Rheumatology Information to Wider Audiences
Since starting the ACR on Air podcast in 2019, Mohammad Ursani, MD, FACP, RhMSUS, has become chair of the Committee on Communications and Marketing. Here, he shares some plans for the ACR website, podcast and more.
Highlights from ACR Convergence’s Late-Breaking Abstracts
COVID-19 vaccination, treatments for rheumatic disease and more—the Late-Breaking Abstracts session of ACR Convergence 2021 highlighted six studies with implications for rheumatology.
How to Differentiate Between & Manage Hypereosinophilic Syndromes & EGPA
Hypereosinophilic syndromes and eosinophilic granulomatosis with polyangiitis (EGPA) represent a spectrum of eosinophilic disorders. Amy D. Klion, MD, provided a detailed overview of this spectrum during ACR Convergence 2021.
Multidisciplinary Guidance for Pulmonary Disease in Sjögren’s Syndrome
Lung disease is common, variable and frequently underdiagnosed in patients with Sjögren’s syndrome. An expert pulmonologist and a rheumatologist discussed the diagnosis and management of pulmonary manifestations of Sjögren’s syndrome during ACR Convergence 2021.
How Do Axial SpA & PsA with Axial Involvement Differ?
The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.
New Data Highlight Effectiveness of Guselkumab for Patients with PsA
The use of guselkumab improved joint and skin symptoms in biologic naive patients with PsA, according to research presented during ACR Convergence 2021.
Tigulixostat Appears Promising for the Treatment of Gout
In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.
FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA
The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.
- « Previous Page
- 1
- …
- 103
- 104
- 105
- 106
- 107
- …
- 805
- Next Page »